FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912137362> ?p ?o ?g. }

• W2912137362 endingPage "809" @default.
• W2912137362 startingPage "799" @default.
• W2912137362 abstract "Objective- Factor XI (FXI) contributes to thrombotic disease while playing a limited role in normal hemostasis. We generated a unique, humanized anti-FXI antibody, AB023, which blocks factor XIIa-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa. We sought to confirm the antithrombotic activity of AB023 in a baboon thrombosis model and to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult subjects. Approach and Results- In a primate model of acute vascular graft thrombosis, AB023 reduced platelet and fibrin accumulation within the grafts by >75%. To evaluate the safety of AB023, we performed a first-in-human study in healthy adult volunteers without any serious adverse events. Overall, 10 of 21 (48%) subjects experienced 20 treatment-emergent adverse events, with 7 of 16 (44%) subjects following active treatment and 3 of 5 (60%) subjects following placebo. AB023 did not increase bleeding or prothrombin times. Anticoagulation was verified by a saturable ≈2-fold prolongation of the partial thromboplastin time for over 1 month after the highest dose. Conclusions- AB023, which inhibits contact activation-initiated blood coagulation in vitro and experimental thrombus formation in primates, produced a dose-dependent duration of limited anticoagulation without drug-related adverse effects in a phase 1 trial. When put in context with earlier observations suggesting that FXI contributes to venous thromboembolism and cardiovascular disease, although contributing minimally to hemostasis, our data further justify clinical evaluation of AB023 in conditions where contact-initiated FXI activation is suspected to have a pathogenic role. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT03097341." @default.
• W2912137362 created "2019-02-21" @default.
• W2912137362 creator A5011450008 @default.
• W2912137362 creator A5017113502 @default.
• W2912137362 creator A5021496734 @default.
• W2912137362 creator A5032261187 @default.
• W2912137362 creator A5036237322 @default.
• W2912137362 creator A5050978437 @default.
• W2912137362 creator A5060358952 @default.
• W2912137362 creator A5060935560 @default.
• W2912137362 creator A5066275678 @default.
• W2912137362 creator A5069151961 @default.
• W2912137362 creator A5071210838 @default.
• W2912137362 creator A5074003801 @default.
• W2912137362 date "2019-04-01" @default.
• W2912137362 modified "2023-10-16" @default.
• W2912137362 title "Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial" @default.
• W2912137362 cites W1577110492 @default.
• W2912137362 cites W1598340191 @default.
• W2912137362 cites W1979338133 @default.
• W2912137362 cites W1984763915 @default.
• W2912137362 cites W1995340369 @default.
• W2912137362 cites W1999608231 @default.
• W2912137362 cites W2002431523 @default.
• W2912137362 cites W2004761712 @default.
• W2912137362 cites W2008751117 @default.
• W2912137362 cites W2016875529 @default.
• W2912137362 cites W2059426768 @default.
• W2912137362 cites W2063706685 @default.
• W2912137362 cites W2071053657 @default.
• W2912137362 cites W2102719739 @default.
• W2912137362 cites W2104825124 @default.
• W2912137362 cites W2117944864 @default.
• W2912137362 cites W2123884212 @default.
• W2912137362 cites W2142092434 @default.
• W2912137362 cites W2143461406 @default.
• W2912137362 cites W2282129983 @default.
• W2912137362 cites W2561678715 @default.
• W2912137362 cites W2585810302 @default.
• W2912137362 cites W2606721249 @default.
• W2912137362 cites W2617972615 @default.
• W2912137362 cites W2753401356 @default.
• W2912137362 cites W2782880902 @default.
• W2912137362 cites W2787493763 @default.
• W2912137362 cites W2809452435 @default.
• W2912137362 cites W2889754070 @default.
• W2912137362 doi "https://doi.org/10.1161/atvbaha.118.312328" @default.
• W2912137362 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6494446" @default.
• W2912137362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30700130" @default.
• W2912137362 hasPublicationYear "2019" @default.
• W2912137362 type Work @default.
• W2912137362 sameAs 2912137362 @default.
• W2912137362 citedByCount "59" @default.
• W2912137362 countsByYear W29121373622019 @default.
• W2912137362 countsByYear W29121373622020 @default.
• W2912137362 countsByYear W29121373622021 @default.
• W2912137362 countsByYear W29121373622022 @default.
• W2912137362 countsByYear W29121373622023 @default.
• W2912137362 crossrefType "journal-article" @default.
• W2912137362 hasAuthorship W2912137362A5011450008 @default.
• W2912137362 hasAuthorship W2912137362A5017113502 @default.
• W2912137362 hasAuthorship W2912137362A5021496734 @default.
• W2912137362 hasAuthorship W2912137362A5032261187 @default.
• W2912137362 hasAuthorship W2912137362A5036237322 @default.
• W2912137362 hasAuthorship W2912137362A5050978437 @default.
• W2912137362 hasAuthorship W2912137362A5060358952 @default.
• W2912137362 hasAuthorship W2912137362A5060935560 @default.
• W2912137362 hasAuthorship W2912137362A5066275678 @default.
• W2912137362 hasAuthorship W2912137362A5069151961 @default.
• W2912137362 hasAuthorship W2912137362A5071210838 @default.
• W2912137362 hasAuthorship W2912137362A5074003801 @default.
• W2912137362 hasBestOaLocation W29121373621 @default.
• W2912137362 hasConcept C111113717 @default.
• W2912137362 hasConcept C112705442 @default.
• W2912137362 hasConcept C126322002 @default.
• W2912137362 hasConcept C144594695 @default.
• W2912137362 hasConcept C186738567 @default.
• W2912137362 hasConcept C197934379 @default.
• W2912137362 hasConcept C2777015399 @default.
• W2912137362 hasConcept C2778261982 @default.
• W2912137362 hasConcept C2778375690 @default.
• W2912137362 hasConcept C2778382381 @default.
• W2912137362 hasConcept C2778589496 @default.
• W2912137362 hasConcept C2780868729 @default.
• W2912137362 hasConcept C3018697912 @default.
• W2912137362 hasConcept C71924100 @default.
• W2912137362 hasConcept C89560881 @default.
• W2912137362 hasConcept C98274493 @default.
• W2912137362 hasConceptScore W2912137362C111113717 @default.
• W2912137362 hasConceptScore W2912137362C112705442 @default.
• W2912137362 hasConceptScore W2912137362C126322002 @default.
• W2912137362 hasConceptScore W2912137362C144594695 @default.
• W2912137362 hasConceptScore W2912137362C186738567 @default.
• W2912137362 hasConceptScore W2912137362C197934379 @default.
• W2912137362 hasConceptScore W2912137362C2777015399 @default.
• W2912137362 hasConceptScore W2912137362C2778261982 @default.
• W2912137362 hasConceptScore W2912137362C2778375690 @default.
• W2912137362 hasConceptScore W2912137362C2778382381 @default.

• next